AAV
Gene Therapy at a Crossroads: Rethinking AAV Amid Industry Resets
Daniel Smith, Ph.D.
Nice Consulting
PAO-05-25-NI-02May 06, 2025
Cell Therapy Capacity
Takeda Opens New R&D Cell Therapy Manufacturing Facility to Support Expansion of Next-Generation Clinical Programs
Takeda
PR-M09-20-NI-17-1291Sep 15, 2020
Sales
Takeda to Sell OTC Drug Unit to Blackstone for $2.3bn
Takeda
PR-M08-20-NI-33Aug 19, 2020
Drug Development
Neurocrine Biosciences and Takeda Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders
Takeda
PR-M06-20-NI-019Jun 16, 2020
Licensing Agreement
ProThera Biologics and Takeda Develop Novel Plasma-Derived Therapy Based on Inter-alpha Inhibitor Proteins
Takeda
PR-M04-20-NI-034Apr 24, 2020
Recall
Takeda Issues US Recall of Two Lots of VONVENDI
Takeda
PR-M02-20-NI-038Feb 27, 2020
Diagnostics
Takeda and Enzyre to Develop Diagnostic Device Allowing Hemophilia Patients to Determine their Coagulation Status at Home
Takeda
PR-M12-19-NI-009Dec 06, 2019
Divest
Takeda Agrees to Divest Select OTC and Non-core Assets to Acino for Over $200 Million USD
Takeda
PR-M10-19-NI-021Oct 15, 2019
Business
Takeda Looks to Sell European Assets
Nice Insight
PAO-M08-19-NI-009Aug 07, 2019
CSR
Takeda Selects Five New Partnerships for Annual Global Corporate Social Responsibility (CSR) Program
Takeda
PR-M07-19-NI-008Jul 05, 2019
Divestiture
Takeda Slimming Down
Nice Insight
PAO-M05-19-NI-018May 21, 2019
Collaboration
Takeda and Frazier Healthcare Partners Announce Collaboration to Launch Phathom Pharmaceuticals
Takeda
PR-M05-19-NI-058May 21, 2019
Announcement
Takeda Opens New Global Research Center in San Diego
Takeda
PR-M05-19-NI-010May 03, 2019
Cell and Gene Therapy
Takeda Collaborates on Gene Therapy Development
Pharma's Almanac
PAO-M04-19-NI-003Apr 02, 2019
Partnership
Takeda and HemoShear Therapeutics Extend Exclusive Drug Discovery Partnership in Liver Diseases
HemoShear Therapeutics
PR-M03-19-NI-059Mar 21, 2019
Real World Data
New Real-World Data Analyses Support the Long-Term Use of Entyvio® (vedolizumab) in Bio-Naïve Patients for the Treatment of Moderate to Severe Ulcerative Colitis or Crohn's Disease
Takeda
PR-M10-18-NI-034Oct 10, 2018
Strategic Collaboration
Crescendo Biologics Reaches Technical Milestone for a Second Target in Strategic Collaboration with Takeda
Crescendo Biologics
PR-M09-18-NI-035Sep 13, 2018
Partnership
Ambys Medicines and Takeda Announce Partnership to Pioneer First-in-Class Therapies for the Treatment of Serious Liver Diseases
Cytotheryx
PR-M08-18-NI-081Aug 21, 2018
Acquisition
Takeda Acquires Shire for $62 Billion
Emilie Branch
Pharma's Almanac
PAO-M05-18-NI-005May 10, 2018
Prescribing Information
TRINTELLIX® Prescribing Information Now Includes New Data Showing Improvement in Processing Speed
Takeda
PR-M05-18-NI-027May 08, 2018